![Eric Richman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Richman
Direktor/Vorstandsmitglied bei
NOVELSTEM INTERNATIONAL CORP.
Vermögen: 601 450 $ am 31.05.2026
Profil
Mr. Eric I.
Richman is a Chairman at Labconnect Holdings, Inc. He is on the Board of Directors at InFUSE Holdings, Inc., NovelStem International Corp., LabConnect, Inc., ADMA Plasma Biologics, Inc., F2g Inc. and Verimmune, Inc. Mr. Richman was previously employed as an Independent Director by NeuBase Therapeutics, Inc., a President, Chief Executive Officer & Director by Tyrogenex, Inc., an Independent Non-Executive Director by ADMA Biologics, Inc., a Vice President-Corporate Development by MaxCyte, Inc., a Partner by Allele Capital Partners, LLC, a Partner by Brace Pharmaceuticals, Inc., and a Director-International Commercialization & Product by MedImmune LLC.
He also served on the board at Gain Therapeutics, Inc., Neubase Therapeutics, Inc. /Old/, ZyVersa Therapeutics Operating, Inc., Therabron Therapeutics, Inc., American Bank (Allentown, Pennsylvania), Lev Pharmaceuticals, Inc., PharmAthene, Inc. and Theraclone Sciences, Inc. He received his undergraduate degree from The Sophie Davis School of Biomedical Education and an MBA from American Graduate School of Management.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
GAIN THERAPEUTICS, INC. 0,71 % | 24.06.2025 | 304 458 ( 0,71 % ) | 593 693 $ | 31.05.2026 |
| 31.12.2024 | 554 054 ( 1,12 % ) | 7 757 $ | 31.05.2026 |
Aktive Positionen von Eric Richman
| Unternehmen | Position | Beginn |
|---|---|---|
| NOVELSTEM INTERNATIONAL CORP. | Direktor/Vorstandsmitglied | 01.06.2018 |
F2g Inc.
 F2g Inc. Pharmaceuticals: OtherHealth Technology F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections, particularly those resistant to current treatments. The company is based in Princeton, NJ. The company leverages proprietary genomic technology and expertise in fungal molecular biology to identify essential fungal genes and develop small-molecule inhibitors called orotomides, which selectively target fungal dihydroorotate dehydrogenase (dhodh), leading to fungal cell death. The company's lead drug candidate, olorofim, is undergoing late-stage clinical development for invasive fungal diseases such as aspergillosis and coccidioidomycosis (valley fever). F2g conducts clinical trials and offers an early access program to provide investigational medicines to patients lacking satisfactory treatment options. | Direktor/Vorstandsmitglied | - |
LabConnect, Inc.
 LabConnect, Inc. Medical/Nursing ServicesHealth Services Provides central laboratory support services | Direktor/Vorstandsmitglied | 01.01.2017 |
Verimmune, Inc.
 Verimmune, Inc. BiotechnologyHealth Technology Specializes in development of anti-tumor immune redirection therapy targeting cancer using pre-existing immune memory | Direktor/Vorstandsmitglied | - |
InFUSE Holdings, Inc.
 InFUSE Holdings, Inc. Medical/Nursing ServicesHealth Services Owns and operates ambulatory infusion centers | Gründer | 01.01.2019 |
Labconnect Holdings, Inc.
 Labconnect Holdings, Inc. Medical/Nursing ServicesHealth Services Provides health care services | Vorsitzender | 15.09.2018 |
ADMA Plasma Biologics, Inc.
 ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology Develops medicines for treatment of infectious diseases | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Eric Richman
| Unternehmen | Position | Ende |
|---|---|---|
| GAIN THERAPEUTICS, INC. | Vorstandsvorsitzender | 20.09.2022 |
| NEUBASE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 26.06.2024 |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Eric Richman
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
24
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 24 |
|---|---|
MedImmune LLC
 MedImmune LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
NovelStem International Corp.
 NovelStem International Corp. BiotechnologyHealth Technology Develops stem-cell-based technologies | Health Technology |
MaxCyte, Inc.
 MaxCyte, Inc. BiotechnologyHealth Technology Specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of therapeutic products | Health Technology |
Theraclone Sciences, Inc.
 Theraclone Sciences, Inc. BiotechnologyHealth Technology Develops therapeutic antibodies for the treatment of infectious disease and inflammation | Health Technology |
ADMA Biologics, Inc.
 ADMA Biologics, Inc. BiotechnologyHealth Technology Develops, manufactures and markets specialty biologics | Health Technology |
Therabron Therapeutics, Inc.
 Therabron Therapeutics, Inc. BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
ZyVersa Therapeutics Operating, Inc.
 ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Lev Pharmaceuticals, Inc.
 Lev Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products for the treatment of inflammatory diseases | Health Technology |
American Graduate School of Management
 American Graduate School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
PharmAthene, Inc.
 PharmAthene, Inc. BiotechnologyHealth Technology Develops bio therapeutics to address biological pathogens and chemicals | Health Technology |
American Bank (Allentown, Pennsylvania)
 American Bank (Allentown, Pennsylvania) Regional BanksFinance State chartered commercial bank | Finance |
ADMA Plasma Biologics, Inc.
ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology Develops medicines for treatment of infectious diseases | Health Technology |
The Sophie Davis School of Biomedical Education
 The Sophie Davis School of Biomedical Education Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tyrogenex, Inc.
 Tyrogenex, Inc. Pharmaceuticals: MajorHealth Technology Offers drug discovery and development focused on small molecule kinase inhibitors | Health Technology |
Brace Pharmaceuticals, Inc.
 Brace Pharmaceuticals, Inc. Investment ManagersFinance Brace Pharmaceuticals invests in companies located in the United States and Brazil. The firm targets companies operating in the fields of bio-pharmaceuticals and biotech. It provides financing for early and late stage capital requirements. | Finance |
Labconnect Holdings, Inc.
Labconnect Holdings, Inc. Medical/Nursing ServicesHealth Services Provides health care services | Health Services |
Neubase Therapeutics, Inc. /Old/
 Neubase Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops peptide-nucleic acid antisense oligonucleotide platform | Health Technology |
Allele Capital Partners, LLC
 Allele Capital Partners, LLC Investment ManagersFinance Allele Capital Partners invests in both public and private companies located in the United States. The firm focuses on a broad range of sectors and industries. It provides debt and equity financing for growth stage capital requirements. | Finance |
NeuBase Therapeutics, Inc.
 NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders | Health Technology |
InFUSE Holdings, Inc.
InFUSE Holdings, Inc. Medical/Nursing ServicesHealth Services Owns and operates ambulatory infusion centers | Health Services |
Gain Therapeutics, Inc.
 Gain Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
LabConnect, Inc.
LabConnect, Inc. Medical/Nursing ServicesHealth Services Provides central laboratory support services | Health Services |
Verimmune, Inc.
Verimmune, Inc. BiotechnologyHealth Technology Specializes in development of anti-tumor immune redirection therapy targeting cancer using pre-existing immune memory | Health Technology |
F2g Inc.
F2g Inc. Pharmaceuticals: OtherHealth Technology F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections, particularly those resistant to current treatments. The company is based in Princeton, NJ. The company leverages proprietary genomic technology and expertise in fungal molecular biology to identify essential fungal genes and develop small-molecule inhibitors called orotomides, which selectively target fungal dihydroorotate dehydrogenase (dhodh), leading to fungal cell death. The company's lead drug candidate, olorofim, is undergoing late-stage clinical development for invasive fungal diseases such as aspergillosis and coccidioidomycosis (valley fever). F2g conducts clinical trials and offers an early access program to provide investigational medicines to patients lacking satisfactory treatment options. | Health Technology |
